Does empiric therapy for atypical pathogens improve outcomes for patients with CAP?
Related Experiment Video
Updated: May 14, 2026

Growing a Cystic Fibrosis-Relevant Polymicrobial Biofilm to Probe Community Phenotypes
Published on: April 19, 2024
Thomas M File1, Thomas J Marrie
1Infectious Disease Section, Department of Internal Medicine, Northeast Ohio Medical University, Rootstown, OH 44272, USA. filet@summahealth.org
Abstract:
The present controversy regarding the need to cover atypical pathogens in the empiric therapy of community-acquired pneumonia is related to several issues, including the relevance of terminology, imprecise diagnostic methods, and perceived contradictory results of published evidence. Studies evaluating the time to clinical recovery and the use of earlier endpoints for evaluation suggest that appropriate therapy provides a benefit if an atypical pathogen is a pathogen. Because recent surveillance studies suggest these pathogens are common and until there is the availability of accurate, cost-effective, and easily interpreted laboratory tests to provide the etiologic diagnosis at the time of point of care, empiric therapy of atypical pathogens is supported.
Related Concept Videos
Acute Pyelonephritis II: Diagnostic Studies and Management
Clinical Significance of Antibiotic Resistance
Atypical Pneumonia
Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Psychosis: Goals of Pharmacotherapy
Drug Therapy
Antianxiety Medications